Nov 9, 2018

National Population and Cost Implications of Treatment with Icosapentyl Ethyl in the United States: An Assessment Based on the REDUCE-IT trial

BioRxiv : the Preprint Server for Biology
Rohan KheraKhurram Nasir

Abstract

Icosapent ethyl, an omega-3-fatty acid, was associated with improved cardiovascular outcomes in individuals with elevated levels of serum triglycerides and at a high-risk of adverse cardiovascular events in the recently completed REDUCE-IT trial. We applied the eligibility criteria of the REDUCE-IT trial to a nationally representative sample of individuals in the United States captured in the National Health and Nutrition Examination Survey (NHANES) for a 6-year period (2009-2014) and estimated the number of individuals nationally that would be potentially eligible for treatment with icosapentyl ethyl. We found that nearly 3 million US adults would potentially be candidates for this therapy. Further, based on the list cost of the drug, if all eligible individuals are treated, the additional cost to the US healthcare system will be almost $9 billion a year.

  • References
  • Citations

References

  • We're still populating references for this paper, please check back later.
  • References
  • Citations

Citations

  • This paper may not have been cited yet.

Mentioned in this Paper

Icosapent ethyl
Omega-3 Fatty Acids
Evaluation
Adverse Event
Pharmacologic Substance
Health Care Systems
National Health and Nutrition Examination Survey
Clinical Trials
Fatty Acids
Serum

About this Paper

Related Feeds

BioRxiv & MedRxiv Preprints

BioRxiv and MedRxiv are the preprint servers for biology and health sciences respectively, operated by Cold Spring Harbor Laboratory. Here are the latest preprint articles (which are not peer-reviewed) from BioRxiv and MedRxiv.